Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vaxcyte, Inc.PCVX · Entity 1164 | EVP, Chief Scientific Ofc, COO | October 05, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vaxcyte, Inc.
Report date October 05, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 145,435 |
Ending reported balance
After 2026-10-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-05 · Exercise / conversion · Acquired 18,000 · Balance 163,435 Row 2 · 2026-10-05 · Sale · Disposed 18,000 · Balance 145,435 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.35 · Expires 2030-04-17 | Direct | 46,398 |
Reported balance
After 2026-10-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-05 · Exercise / conversion · Disposed 18,000 · Balance 46,398 F2: Stock Option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025.
F2: Stock Option is fully vested and exercisable.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Icosavax, Inc.
Report date February 19, 2024 · Filed February 21, 2024
Section 16 reporting ended · disclosed 2024-02-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-02-19 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2024-02-19 · Other · Disposed 3,695 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of December 11, 2023 (the "Merger Agreement"), by and among the Issuer, AstraZeneca Finance and Holdings Inc. ("Parent"), and Isochrone Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock at a purchase price per share of (i) $15.00 plus (ii) one non-tradable contingent value right ("CVR") per share representing the right to receive a contingent payment of up to $5.00 in cash upon achievement of specified milestones (collectively, the "Offer Price"). After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of February 19, 2024 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-02-19 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2024-02-19 · Disposition to issuer · Disposed 7,392 · Balance 0 F2: Represents restricted stock units ("RSUs"). Pursuant to the Merger Agreement, immediately prior to the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive the Offer Price, subject to the terms of the Merger Agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.25 | Direct | 0 |
Reported balance
After 2024-02-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-02-19 · Disposition to issuer · Disposed 44,556 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.89 | Direct | 0 |
Reported balance
After 2024-02-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-19 · Disposition to issuer · Disposed 17,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the terms of an Agreement and Plan of Merger, dated as of December 11, 2023 (the "Merger Agreement"), by and among the Issuer, AstraZeneca Finance and Holdings Inc. ("Parent"), and Isochrone Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock at a purchase price per share of (i) $15.00 plus (ii) one non-tradable contingent value right ("CVR") per share representing the right to receive a contingent payment of up to $5.00 in cash upon achievement of specified milestones (collectively, the "Offer Price"). After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of February 19, 2024 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent.
F2: Represents restricted stock units ("RSUs"). Pursuant to the Merger Agreement, immediately prior to the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive the Offer Price, subject to the terms of the Merger Agreement.
F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 05, 2026 Filed Oct 7, 2026 20:08 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001813798-26-000023 · wk-form4_1791403730.xml · derivative · entry 3 Wassil Jim · CIK 0001813798 · EVP, Chief Scientific Ofc, COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,398 Underlying: Common Stock · 18,000 shares Expires 2030-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Stock Option is fully vested and exercisable. Read SEC document |
| October 05, 2026 Filed Oct 7, 2026 20:08 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 18,000 | $86.74 | $1,561,320.00 |
DisclosureSEC source: 0001813798-26-000023 · wk-form4_1791403730.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · EVP, Chief Scientific Ofc, COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 145,435 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. Read SEC document |
| October 05, 2026 Filed Oct 7, 2026 20:08 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 18,000 | $5.35 | $96,300.00 |
DisclosureSEC source: 0001813798-26-000023 · wk-form4_1791403730.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · EVP, Chief Scientific Ofc, COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 163,435 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 00:05 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 2,250 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001813798-26-000021 · wk-form4_1790971547.xml · derivative · entry 4 Wassil Jim · CIK 0001813798 · EVP, Chief Scientific Ofc, COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,398 Underlying: Common Stock · 2,250 shares Expires 2030-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Stock Option is fully vested and exercisable. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 00:05 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 95 | $57.09 | $5,423.93 |
DisclosureSEC source: 0001813798-26-000021 · wk-form4_1790971547.xml · nonDerivative · entry 3 Wassil Jim · CIK 0001813798 · EVP, Chief Scientific Ofc, COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 145,435 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $57.09 to $57.10. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 00:05 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 2,155 | $56.65 | $122,089.37 |
DisclosureSEC source: 0001813798-26-000021 · wk-form4_1790971547.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · EVP, Chief Scientific Ofc, COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 145,530 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $56.065 to $56.955. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 00:05 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 2,250 | $5.35 | $12,037.50 |
DisclosureSEC source: 0001813798-26-000021 · wk-form4_1790971547.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · EVP, Chief Scientific Ofc, COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 147,685 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 09, 2026 Filed Sep 9, 2026 21:46 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,334 | $59.52 | $79,401.01 |
DisclosureSEC source: 0001813798-26-000019 · wk-form4_1788990392.xml · nonDerivative · entry 3 Wassil Jim · CIK 0001813798 · EVP, Chief Scientific Ofc, COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,435 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. F4 · shares: The price reported is a weighted-average price. The shares were sold at prices ranging from $59.155 to $60.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 08, 2026 Filed Sep 9, 2026 21:46 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 5,459 | $60.36 | $329,505.24 |
DisclosureSEC source: 0001813798-26-000019 · wk-form4_1788990392.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · EVP, Chief Scientific Ofc, COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,769 F3 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Read SEC document |
| September 04, 2026 Filed Sep 9, 2026 21:46 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,381 | $61.16 | $84,461.96 |
DisclosureSEC source: 0001813798-26-000019 · wk-form4_1788990392.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · EVP, Chief Scientific Ofc, COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,228 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. F2 · shares: The price reported is a weighted-average price. The shares were sold at prices ranging from $60.95 to $61.57. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 02, 2026 Filed Sep 2, 2026 23:58 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 1,432 | $61.58 | $88,182.56 |
DisclosureSEC source: 0001813798-26-000017 · wk-form4_1788393516.xml · nonDerivative · entry 7 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,609 F1 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Read SEC document |
| September 01, 2026 Filed Sep 2, 2026 23:58 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 2,250 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001813798-26-000017 · wk-form4_1788393516.xml · derivative · entry 8 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,648 Underlying: Common Stock · 2,250 shares Expires 2030-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Stock Option is fully vested and exercisable. Read SEC document |
| September 01, 2026 Filed Sep 2, 2026 23:58 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 303 | $61.42 | $18,611.47 |
DisclosureSEC source: 0001813798-26-000017 · wk-form4_1788393516.xml · nonDerivative · entry 6 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,041 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. F6 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $61.34 to $61.48. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 01, 2026 Filed Sep 2, 2026 23:58 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 924 | $60.96 | $56,322.42 |
DisclosureSEC source: 0001813798-26-000017 · wk-form4_1788393516.xml · nonDerivative · entry 5 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,344 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. F5 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $60.29 to $61.22. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 01, 2026 Filed Sep 2, 2026 23:58 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 713 | $61.48 | $43,835.95 |
DisclosureSEC source: 0001813798-26-000017 · wk-form4_1788393516.xml · nonDerivative · entry 4 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,268 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $61.31 to $62.04. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 01, 2026 Filed Sep 2, 2026 23:58 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,537 | $60.89 | $93,581.78 |
DisclosureSEC source: 0001813798-26-000017 · wk-form4_1788393516.xml · nonDerivative · entry 3 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,981 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $60.29 to $61.275. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 01, 2026 Filed Sep 2, 2026 23:58 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 2,250 | $5.35 | $12,037.50 |
DisclosureSEC source: 0001813798-26-000017 · wk-form4_1788393516.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,518 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2026 Filed Sep 2, 2026 23:58 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 1,273 | $60.74 | $77,322.02 |
DisclosureSEC source: 0001813798-26-000017 · wk-form4_1788393516.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,268 F1 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Read SEC document |
| August 03, 2026 Filed Aug 5, 2026 20:59 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 2,250 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001813798-26-000015 · wk-form4_1785963547.xml · derivative · entry 4 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,898 Underlying: Common Stock · 2,250 shares Expires 2030-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Stock Option is fully vested and exercisable. Read SEC document |
| August 03, 2026 Filed Aug 5, 2026 20:59 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,389 | $54.09 | $75,129.62 |
DisclosureSEC source: 0001813798-26-000015 · wk-form4_1785963547.xml · nonDerivative · entry 3 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 157,541 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $53.935 to $54.36. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 03, 2026 Filed Aug 5, 2026 20:59 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 861 | $53.50 | $46,065.22 |
DisclosureSEC source: 0001813798-26-000015 · wk-form4_1785963547.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 158,930 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $52.915 to $53.91. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 03, 2026 Filed Aug 5, 2026 20:59 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 2,250 | $5.35 | $12,037.50 |
DisclosureSEC source: 0001813798-26-000015 · wk-form4_1785963547.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 159,791 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 781 shares acquired under the Issuer's Employee Stock Purchase Plan on May 15, 2026. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 22:25 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 516 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001813798-26-000013 · wk-form4_1783376751.xml · derivative · entry 5 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,148 Underlying: Common Stock · 516 shares Expires 2030-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Stock Option is fully vested and exercisable. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 22:25 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 6 | $57.82 | $346.92 |
DisclosureSEC source: 0001813798-26-000013 · wk-form4_1783376751.xml · nonDerivative · entry 4 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 156,760 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 22:25 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 456 | $57.47 | $26,207.69 |
DisclosureSEC source: 0001813798-26-000013 · wk-form4_1783376751.xml · nonDerivative · entry 3 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 156,766 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $56.695 to $57.59. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 22:25 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,788 | $56.03 | $100,181.64 |
DisclosureSEC source: 0001813798-26-000013 · wk-form4_1783376751.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 157,222 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $55.60 to $56.595. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 22:25 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 516 | $5.35 | $2,760.60 |
DisclosureSEC source: 0001813798-26-000013 · wk-form4_1783376751.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 159,010 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 20:59 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 301 | $50.26 | $15,127.36 |
DisclosureSEC source: 0001813798-26-000011 · wk-form4_1780520351.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 158,494 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $50.205 to $51.01. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 20:59 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,949 | $49.40 | $96,288.40 |
DisclosureSEC source: 0001813798-26-000011 · wk-form4_1780520351.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 158,795 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $49.03 to $49.93. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 01, 2026 Filed May 1, 2026 21:37 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 2,250 | $56.83 | $127,869.75 |
DisclosureSEC source: 0001813798-26-000010 · wk-form4_1777671471.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 160,744 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $56.425 to $57.26. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:06 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 838 | $58.93 | $49,385.02 |
DisclosureSEC source: 0001813798-26-000008 · wk-form4_1775246763.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 162,994 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $58.74 to $59.215. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F4 · balance_after: The Reporting Person entered into a divorce settlement agreement with his ex-spouse (the "Settlement Agreement") pursuant to a "domestic relations order" as defined in Section 16(a)(12) of the Securities Exchange Act of 1934, as amended. On March 25 and 26, 2026, the Reporting Person transferred 962 and 612 shares, respectively, of Vaxcyte, Inc. Common Stock to his ex-spouse pursuant to the Settlement Agreement. Accordingly, the Reporting Person will not report beneficial ownership of or dispositions of the disposed shares in future Section 16(a) filings. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:06 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,412 | $58.14 | $82,090.86 |
DisclosureSEC source: 0001813798-26-000008 · wk-form4_1775246763.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 165,406 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $57.695 to $58.69. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 21:23 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 4,968 | $59.16 | $293,906.88 |
DisclosureSEC source: 0001813798-26-000005 · wk-form4_1773264193.xml · nonDerivative · entry 3 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 166,818 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $58.74 to $59.575. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 21:23 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 2,427 | $58.32 | $141,532.93 |
DisclosureSEC source: 0001813798-26-000005 · wk-form4_1773264193.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 171,786 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $57.725 to $58.715. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 21:23 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 975 | $59.32 | $57,837.00 |
DisclosureSEC source: 0001813798-26-000005 · wk-form4_1773264193.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 174,213 F1 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. No other shares of common stock subject to the restrictions on transfer set forth in a Lock-Up Agreement dated January 29, 2026 were sold by the Reporting Person. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 01:06 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 1,009 | $61.98 | $62,537.82 |
DisclosureSEC source: 0001813798-26-000003 · wk-form4_1772500000.xml · nonDerivative · entry 5 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,188 F3 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Read SEC document |
| February 28, 2026 Filed Mar 3, 2026 01:06 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 898 | $61.98 | $55,658.04 |
DisclosureSEC source: 0001813798-26-000003 · wk-form4_1772500000.xml · nonDerivative · entry 4 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,197 F3 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 01:06 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 1,900 | $61.74 | $117,306.00 |
DisclosureSEC source: 0001813798-26-000003 · wk-form4_1772500000.xml · nonDerivative · entry 3 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 177,095 F3 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 01:06 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 5,102 | $61.74 | $314,997.48 |
DisclosureSEC source: 0001813798-26-000003 · wk-form4_1772500000.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,995 F2 · shares: Represents RSUs issued in lieu of a cash bonus by election of the Reporting Person, such election available to all of Issuer's senior management. The RSUs are fully vested upon the date of grant. Read SEC document |
| February 26, 2026 Filed Mar 3, 2026 01:06 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 53,566 | $0.00 Strike: $60.00 | $0.00 |
DisclosureSEC source: 0001813798-26-000003 · wk-form4_1772500000.xml · derivative · entry 6 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,566 Underlying: Common Stock · 53,566 shares Expires 2036-02-26 F4 · derivative.exercise_date: 1/48 of shares subject to the option vest on March 26, 2026, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| February 26, 2026 Filed Mar 3, 2026 01:06 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 32,045 | $0.00 | $0.00 |
DisclosureSEC source: 0001813798-26-000003 · wk-form4_1772500000.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,893 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 1/4 of the shares subject to the award on September 7, 2026 and 1/8 of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| September 08, 2025 Filed Sep 10, 2025 20:27 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 2,759 | $32.41 | $89,419.19 |
DisclosureSEC source: 0001813798-25-000005 · wk-form4_1757536046.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,848 F1 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. F2 · balance_after: The Reporting Person entered into a divorce settlement agreement with his ex-spouse (the Settlement Agreement") pursuant to a "domestic relations order" as defined in Section 16(a)(12) of the Securities Exchange Act of 1934, as amended. On September 9, 2025, the Reporting Person transferred 1,663 shares of Vaxcyte, Inc. Common Stock to his ex-spouse pursuant to the Settlement Agreement. Accordingly, the Reporting Person will not report beneficial ownership of or dispositions of the disposed shares in future Section 16(a) filings. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 20:11 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 1,429 | $31.56 | $45,099.24 |
DisclosureSEC source: 0001813798-25-000004 · wk-form4_1757016692.xml · nonDerivative · entry 3 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,270 F1 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 20:11 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 1,587 | $31.56 | $50,085.72 |
DisclosureSEC source: 0001813798-25-000004 · wk-form4_1757016692.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,699 F1 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 20:11 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 1,270 | $31.56 | $40,081.20 |
DisclosureSEC source: 0001813798-25-000004 · wk-form4_1757016692.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,286 F1 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. F2 · balance_after: The Reporting Person entered into a divorce settlement agreement with his ex-spouse (the Settlement Agreement") pursuant to a "domestic relations order" as defined in Section 16(a)(12) of the Securities Exchange Act of 1934, as amended. On April 1, 2025, the Reporting Person transferred 1,689 shares of Vaxcyte, Inc. Common Stock to his ex-spouse pursuant to the Settlement Agreement. Accordingly, the Reporting Person will not report beneficial ownership of or dispositions of the disposed shares in future Section 16(a) filings. F3 · balance_after: Includes 329 shares acquired under the Issuer's Employee Stock Purchase Plan on May 16, 2025. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 02:14 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 5,362 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001649094-25-000039 · wk-form4_1741054462.xml · derivative · entry 12 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,664 Underlying: Common Stock · 5,362 shares Expires 2030-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Option is fully vested and exercisable. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 02:14 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 2,638 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001649094-25-000039 · wk-form4_1741054462.xml · derivative · entry 11 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,638 shares Expires 2029-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Option is fully vested and exercisable. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 02:14 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 3,015 | $72.10 | $217,381.50 |
DisclosureSEC source: 0001649094-25-000039 · wk-form4_1741054462.xml · nonDerivative · entry 9 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 151,916 F3 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 02:14 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 2,085 | $73.84 | $153,950.15 |
DisclosureSEC source: 0001649094-25-000039 · wk-form4_1741054462.xml · nonDerivative · entry 8 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 154,931 F4 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024. F6 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $73.51 to $74.41. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 02:14 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 5,915 | $73.07 | $432,214.97 |
DisclosureSEC source: 0001649094-25-000039 · wk-form4_1741054462.xml · nonDerivative · entry 7 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 157,016 F4 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024. F5 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $72.50 to $73.47. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.